ZENERGY (03677) released its interim results, reporting a net profit attributable to shareholders of 372 million yuan, a year-on-year increase of 68.6%. The revenue from its power battery business grew by 53.3% compared to the previous year.
Zhengli New Energy (03677) announced its interim results for the six months ended June 30, 2026, with revenue of RMB 5.438 billion, a year-on-year increase of 71.45%; profit attributable to shareholders of RMB 372 million, a year-on-year increase of 68.6%; and earnings per share of RMB 0.15.
ZENERGY (03677) announced its interim results for the six months ending June 30, 2026, with the group revenue reaching RMB 5.438 billion, a year-on-year increase of 71.45%; shareholders' attributable profit amounted to RMB 372 million, up 68.6%; and earnings per share were RMB 0.15.
From January to June 2026, the groups sales revenue from power battery business was RMB 4.577 billion, representing a year-on-year growth of 53.3%; the groups power battery shipment was 11.13 GWh. According to data from the China Automotive Power Battery Industry Innovation Alliance, from January to June 2026, the companys domestic power battery installation volume and market share continued to rise year-on-year, with the companys ranking in the installed capacity of new energy passenger vehicles improving from seventh place last year to fifth place.
The announcement stated that the revenue growth was primarily driven by a significant year-on-year increase in the shipment of power and energy storage batteries, which contributed to the rise in the companys sales revenue.
Related Articles

BAIJUYI HOLD (08081) announced its interim results, reporting a loss attributable to owners of HKD 15.22 million, a year-on-year narrowing of 20.88%.

OCUMENSION-B (01477): OT-202 Phase III clinical trial completes enrollment of the first patient.

FUTURE BRIGHT (00703) released its mid-term results, reporting a loss attributable to shareholders of HKD 1.651 million.
BAIJUYI HOLD (08081) announced its interim results, reporting a loss attributable to owners of HKD 15.22 million, a year-on-year narrowing of 20.88%.

OCUMENSION-B (01477): OT-202 Phase III clinical trial completes enrollment of the first patient.

FUTURE BRIGHT (00703) released its mid-term results, reporting a loss attributable to shareholders of HKD 1.651 million.

RECOMMEND





